Evaluation of increasing doses of gemfibrozil in hyperlipoproteinaemia.
D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D003402:Creatine Kinase / Q000097:blood; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000201:enzymology; D000960:Hypolipidemic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D010919:Placebos; D013997:Time Factors; D014280:Triglycerides / Q000097:blood; D014631:Valerates / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D014992:Xylenes / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
D000960:Hypolipidemic Agents; D010919:Placebos; D014280:Triglycerides; D014631:Valerates; D014992:Xylenes; D002784:Cholesterol; D001219:Aspartate Aminotransferases; D003402:Creatine Kinase; D000469:Alkaline Phosphatase